I have been a professional IT financial systems consultant for over 25 years and a non-professional investor for an equally long period. My blog, Click Broker (http://clickbroker.blogspot.com/), contains opinions and humor about stocks, economics, consumers, and politics. I am generally a contrarian.
Retired. Age 70. Live in Florida. Varied work experience from Mechanical Engineering and Machine Shop to teaching and small business owner. Attended Northeastern University for 3 years.
Interested in investing and trading equities to include penny stocks and day trading.
History- 31 years in the computer industry, 10 with Microsoft in the 'golden' years - 1990-2000. Retired in 2000, found a second career in 2009, trading options under the guidance of a new friend and mentor. Enjoying life and my new adventure, helping family and friends recover from their losses in 2008 and live a comfortable life in their retirement years.
Have been an investor for 60 years. Last 20 years have concentrated on biotechs. Have been senior exec with Shell and ITT before retiring 30+ years ago. My working areas were finance, informatics and international management. Taught MBA courses in management, informatics and communications. Speak French and Spanish plus some German.
I am not an investment professional. I do not engage in stock or currency trading. I am a blogger and investor who believes the failure of credit has created an investment demand for gold, and that gold bullion is the sole means of wealth preservation.
I have just returned to Australia after 18 years in Singapore & Malaysia doing private wealth management with some of the world’s best banks.
My skill is in finding low risk global equities opportunities of all types, to reduce the risk of a client’s portfolio. My focus is for capital preservation with a decent yield using my global experience
Mike Wokasch, a pharmacist by training, is a 30 year pharmaceutical industry veteran, having held a number of positions of increasing responsibility at several large pharmaceutical companies including Merck, Bayer, Abbott,and Chiron . Among his notable commercial accomplishments was helping with the successful US launch of the blockbuster antibiotic Cirpo® (ciprofloxacin). Mr. Wokasch has also been an executive at a number of technology based companies including Promega, Vertex subsidiaries (PanVera, and Aurora Biosciences), and was Corporate Sr. Vice President and President of the global early development division of Covance.
He is an author of the recently published book, Pharmaplasia™, which is about the changes needed in the pharmaceutical industry as it adapts to healthcare reform. He enjoys speaking about the pharmaceutical industry and also authors a blog at www.PharmaReform.com